MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rpsm.2014.05.004

Медицинская библиотека · Revista de psiquiatria y salud mental · 2014

Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description.

Pina-Camacho Laura, Díaz-Caneja Covadonga M, Saiz Pilar A, Bobes Julio, Corripio Iluminada, Grasa Eva, Rodriguez-Jimenez Roberto, Fernández Miryam, Sanjuán Julio, García-López Aurelio, Tapia-Casellas Cecilia, Álvarez-Blázquez María, Fraguas David, Mitjans Marina, Arias Bárbara, Arango Celso

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIM: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-individual genetic differences produce varying degrees of vulnerability to the different SGA-induced side effects. The Second-generation antipsychotic Long-term treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental and genetic factors that explain inter-individual differences in weight gain and metabolic changes in drug-naïve patients after six months of treatment with SGAs.

MATERIALS AND

METHODS

The SLIM study is a multicenter, observational, six-month pharmacogenetic study where a cohort of 307 drug-naïve paediatric and adult patients (age range 8.8-90.1 years) and a cohort of 150 age- and sex- matched healthy controls (7.8-73.2 years) were recruited.

RESULTS

This paper describes the rationale, objectives and design of the study and provides a description of the sample at baseline.

CONCLUSIONS

Results from the SLiM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment.

Для цитирования: Pina-Camacho Laura, Díaz-Caneja Covadonga M, Saiz Pilar A, Bobes Julio, Corripio Iluminada, Grasa Eva, Rodriguez-Jimenez Roberto, Fernández Miryam, Sanjuán Julio, García-López Aurelio, Tapia-Casellas Cecilia, Álvarez-Blázquez María, Fraguas David, Mitjans Marina, Arias Bárbara, Arango Celso. Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): rationale, objectives, design and sample description.. Revista de psiquiatria y salud mental. 2014. DOI: 10.1016/j.rpsm.2014.05.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.